Essential Copy Rules - Mpje

1. What does "commercially available" generally mean for essential-copy determinations?

   FDA-approved and available on the market (not discontinued or unavailable). Commercial availability requires active marketing and accessibility, ensuring compounding is not used as a substitute for obtainable approved drugs.

2. Which factor is most relevant to "commercially available" status: FDA approval or whether a pharmacy can obtain it promptly?

   Availability on the market (practical availability), not just FDA approval. Practical availability ensures the commercial product can be obtained, making compounding unnecessary unless truly unavailable.

3. Which change most clearly makes a compounded product NOT an essential copy: different API or only different excipient?

   Different active ingredient(s) (different API). Changing the API fundamentally alters the drug's identity, clearly distinguishing it from the commercial product under FDA criteria.

4. Identify whether this is an essential copy: same API and route, but different dosage form (capsule vs solution).

   No, not an essential copy (dosage form differs). Variations in dosage form change the product's physical presentation and delivery, preventing it from being deemed essentially the same.

5. Identify whether this supports "significant difference" under 503A: allergy to a dye in the commercial product.

   Yes, excipient allergy can be a significant difference. Allergies to excipients in commercial versions create a medical need for alteration, qualifying as a significant difference per FDA.

6. Under 503A, who must determine the "significant difference" that justifies compounding an essential copy?

   The prescriber (for the individual patient). FDA requires the prescriber's medical judgment to confirm a clinical need, ensuring compounding is not for convenience or cost reasons.

7. Identify whether this is an essential copy: same API and strength, but different route (oral vs topical).

   No, not an essential copy (route differs). Differences in route alter how the drug is administered and absorbed, making it non-identical under FDA essential copy guidance.

8. Identify whether this is permitted under 503B: compounding a copy of a drug currently on the FDA shortage list.

   Yes, generally permitted while the drug is on the shortage list. Shortage listing establishes clinical need, providing an exception under 503B to ensure patient access during supply disruptions.

9. What is the key compliance implication if a product is an essential copy and no exception applies?

   It violates compounding conditions and loses 503A/503B enforcement protections. Without exceptions, such compounding is treated as unapproved drug manufacturing, exposing facilities to FDA enforcement actions.

10. What is the safest MPJE approach when facts are unclear on essential-copy status?

    Treat as an essential copy unless a clear exception and documentation exist. MPJE emphasizes caution to avoid violations, requiring clear evidence of exceptions to maintain compliance with FDA policies.

11. What is the general compliance rule for compounding an essential copy under section 503B?

    Prohibited if it is essentially a copy unless it meets an allowed exception. Section 503B prohibits copies to ensure outsourcing facilities do not compete with approved manufacturers except in cases like shortages.

12. Under FDA policy, what is the typical effect of compounding "regularly or in inordinate amounts" of a copy?

    It is evidence of noncompliance and increased enforcement risk. FDA views frequent or large-scale copy compounding as indicative of improper manufacturing, heightening scrutiny and potential penalties.

13. Identify whether this supports "significant difference" under 503A: changing flavor only to improve palatability.

    No, flavor change alone is typically not a significant difference. Mere palatability changes lack clinical necessity, failing to meet FDA's threshold for significant differences justifying compounding copies.

14. Under 503A, is "patient preference" alone typically sufficient to justify compounding an essential copy?

    No, preference alone is not a significant difference. FDA guidance specifies that significant differences must be clinical, not merely preferential, to justify bypassing commercial products.

15. Identify whether this is an essential copy: same API, same strength, same dosage form, same route.

    Yes, it is an essential copy (essentially the same). Matching all key attributes means the compounded drug duplicates the commercial product, violating copy restrictions without exceptions.

16. What is the general compliance rule for compounding an essential copy under section 503A?

    Prohibited unless a documented significant difference exists for the patient. Section 503A restricts such compounding to protect the integrity of FDA-approved drugs unless a patient-specific medical need is documented.

17. Which list is used for 503B to permit compounding when there is a clinical need despite available products?

    The FDA drug shortage list (when the drug is in shortage). This list identifies shortages creating clinical need, allowing 503B facilities to compound copies temporarily to address supply gaps.

18. Under 503B, what is the common term for compounding a drug that is essentially a copy without meeting an exception?

    Impermissible "copy" compounding (essential copy violation). This term describes violations where 503B facilities compound duplicates without exceptions, risking loss of regulatory exemptions.

19. Identify whether this is an essential copy: same API and dosage form, but strength differs (e.g., $5$ mg vs $10$ mg).

    No, not an essential copy (strength differs). Strength variations create a distinct product, as FDA assesses copies based on matching key attributes including exact dosage strength.

20. What is an "essential copy" under FDA compounding policy for 503A/503B products?

    A compounded drug that is essentially the same as a commercially available drug. FDA defines it to prevent compounding from undermining the drug approval process by duplicating approved products without justification.

21. Under 503A, what documentation is required to justify compounding an otherwise essential copy for a patient?

    Prescriber determination of significant difference documented on the prescription. This ensures the compounding addresses a patient-specific clinical need, providing legal justification under FDA's 503A policy.

22. Identify the compliance outcome under 503A: essential copy compounded without prescriber-documented significant difference.

    Noncompliant; not eligible for 503A protections (subject to enforcement). Lacking documentation violates 503A conditions, treating the activity as unapproved manufacturing open to FDA regulatory action.

23. Identify whether this is an essential copy: same API, strength, form, route, but different release type (IR vs ER).

    No, not an essential copy (release characteristics differ). Differences in release mechanisms affect pharmacokinetics, rendering the compounded drug non-identical to the commercial version.

24. What FDA term is used for the reference product when assessing "essential copy" status?

    A commercially available drug product. FDA uses this term to compare the compounded version against an approved, marketed product for essential copy evaluations.

Study these flashcards